Hoffmann-la Roche Inc.

Madrigal Pharmaceuticals, Inc.

Via Pharmaceuticals, Inc.

F. Hoffmann-la Roche Ag

Lee Apostle McDermott

Yimin Qian

Matthew Michael Hamilton

David Robert Bolin

Adrian Wai-Hing Cheung

Fariborz Firooznia

Weiya Yun

Jefferson Wright Tilley

Zhuming Zhang

Ramakanth Sarabu

Robert Francis Kester

Nancy-Ellen Haynes

Norman Kong

Steven Joseph Berthel

Nathan Robert Scott

Jenny Tan

Nicholas J S Huby

John Anthony Moliterni

Robert Alan Goodnow, Jr

Nader Fotouhi

Xin-Jie Chu

Lin Yi

John A Brinkman

Stuart Hayden

Nicholas Marcopulos

Shiming Li

Provided herein are compounds of the formula (I): were RI is phenyl, R2 is hydrogen, halogen or lower alkyl, X is carbon on nitrogen, and R3 is isoquinoline, -amino, or a -4- to 6-membered heterocycloalkyl ring and pharmaceutically acceptable salts thereof, which are active as DGAT inhibitors and therefore find uses in treatment of diseases associated with abnormal metabolism of trigliceride. such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

Diacylglycerol acyltransferase inhibitors

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

Pyridazinone glucokinase activators

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

Indole and indazole analogs as glycogen synthase activators

Pyrrolidinone glucokinase activators

The present invention relates to compounds of the formula which are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as, cancer, cognative and CNS disorders and inflammatory/autoimmune diseases.

Substituted hydantoins

Growing community of inventors

East Windsor, NJ, United States of America

Lee Apostle McDermott